We further assessed the treatment effects of the BTK inhibitor Acalabrutinib on NSCLC cell lines with different EGFR status, namely A549 (wild-type EGFR), H1975 (EGFR T790M), and PC-9 (mutant EGFR with exon 19 deletion) cells. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.